Today's Daily Dose brings you news about FDA approval of Bristol-Myers' Opdivo and Merck's Keytruda for additional indications; Allergan's disappointment over its antipsychotic medicine VRAYLAR and Auris' progress with its phase III clinical trial of Keyzilen.
from RTT - Biotech http://ift.tt/2xzg2ZO
via IFTTT
No comments:
Post a Comment